quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:04·269d
SECFiling
Verve Therapeutics Inc. logo

SEC Form EFFECT filed by Verve Therapeutics Inc.

VERV· Verve Therapeutics Inc.
Health Care
Original source

Companies

  • VERV
    Verve Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 15UpdateCantor Fitzgerald-
  • Apr 8UpdateH.C. Wainwright$15.00
  • Apr 13UpdateCanaccord Genuity$29.00
  • Feb 1UpdateCantor Fitzgerald$21.00
  • Dec 15UpdateGoldman$13.00
  • Oct 6UpdateCredit Suisse$48.00

Related

  • SEC262d
    SEC Form 15-12G filed by Verve Therapeutics Inc.
  • SEC269d
    Amendment: SEC Form SCHEDULE 13G/A filed by Verve Therapeutics Inc.
  • INSIDER269d
    SEC Form 4 filed by Director Maclean Michael F
  • INSIDER269d
    SEC Form 4 filed by Director Yeshwant Krishna
  • INSIDER269d
    Chief Administrative Officer Nickerson Joan closing all direct ownership in the company (SEC Form 4)
  • INSIDER269d
    Chief Executive Officer Kathiresan Sekar closing all direct ownership in the company (SEC Form 4)
  • INSIDER269d
    Chief Scientific Officer Lister Troy closing all direct ownership in the company (SEC Form 4)
  • INSIDER269d
    Chief Financial Officer Dorval Allison closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022